DFB Pharmaceuticals
Practical innovations for life
Banner-sand.jpg

News

We're making waves.

News

Nanology to present at Bio investor forum on October 17, 2017 in san Francisco

DALLAS/FT.WORTH, (September 26, 2017) —NanOlogy™, a clinical-stage pharmaceutical development company, announced today that VP of Medical Affairs Gere diZerega, MD, will present at the BIO Investor Forum conference Tuesday, October 17 at 9:45 am at the Westin St. Francis in San Francisco. The presentation will cover the status of the company’s clinical development program and how its nanoparticle technology platform aims to transform systemic chemotherapy into local delivery of proven drugs.

DFB Soria gives update on enrollment of phase 2 clinical trial of sor007 (nanoparticle paclitaxel) ointment for actinic keratosis (AK)

DALLAS/FT.WORTH, (September 26, 2017) —DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy, today announced completion of the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle paclitaxel formed by a proprietary production process. Identified as SOR007, the ointment is being evaluated topically in a dose escalating trial for safety and preliminary efficacy.

drug development and delivery article on formation of NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform

September 14, 2017 – Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much of the attention in recent years, but the first generation of these drugs has not delivered the hoped for panacea and development of more effective, safer immunotherapies is still years from reaching patients. In addition, immunotherapy is extremely expensive with treatment costs easily reaching $100,000 or more annually per patient.

 

DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses

September 12, 2017 – DFB Pharmaceuticals, a private investment and development group, in collaboration with CritiTech and US Biotest, has formed NanOlogy to finance and develop a breakthrough technology platform to produce unique, patented, naked nanoparticle forms of paclitaxel and docetaxel for local delivery with the potential for greater efficacy and safety to treat cancer and other serious illnesses.

Fort Worth entrepreneur, business executive provides tuition scholarships for new M.D. school

April 18, 2017 – In a show of support for the new TCU and UNTHSC School of Medicine, Fort Worth pharmaceutical executive, business investor and entrepreneur Paul Dorman will provide full first-year tuition to the inaugural class of medical students.

smith & nephew to acquire us bioactive wound care business for $782 million

November 28, 2012 – Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces that it is strengthening its global position in advanced wound care by entering into an agreement through its subsidiaries to acquire substantially all the assets of Healthpoint Biotherapeutics (“Healthpoint”), a leader in bioactive debridement, dermal repair and regeneration wound care treatments, for $782 million in cash.

Roundtable healthcare partners portfolio company, renaissance acquisition holdings, LLC Acquires dpt Laboratories

LAKE FOREST, IL, July 5, 2012 — RoundTable Healthcare Partners (“RoundTable”), an operating‐oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Renaissance Acquisition Holdings, LLC (“Renaissance”), has acquired DPT Laboratories Inc. (“DPT”).